The results show a rapid and significant reduction in depression symptoms just three weeks after a single 12mg dose, with an unprecedented -14 point decrease on the MADRS scale compared to a placebo. This remarkable improvement surpasses the average 1.82-point improvement seen in current standard antidepressants. Additionally, CYB003 demonstrates a robust response and remission in a substantial percentage of patients, with a favorable safety profile at the 12mg dose. The full top-line data is expected in Q4 2023, marking a significant leap in depression treatment! $CYBN https://www.businesswire.com/news/home/20231031220551/en/Cybin-Announces-Unprecedented-Positive-Phase-2-Interim-Data-for-CYB003-in-Major-Depressive-Disorder-Meeting-Primary-Efficacy-Endpoint-with-Rapid-and-Significant-Improvements-in-Depression-Symptoms-After-Single-Dose
Leave a Reply